SCHEMBL23658147

SCHEMBL23658147

CCCC(=O)N1CCNC[C@H]1C(=O)C(C)C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.34
DPP7 Q9UHL4 1/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNA3 P32297 1/20 0.34
CHRNA4 P43681 1/20 0.34
CHRNB3 Q05901 1/20 0.34
CHRNA6 Q15825 1/20 0.34
HCRTR2 O43614 1/20 0.32
GNAI3 P08754 4/20 0.31
GNAO1 P09471 4/20 0.31
GNAI1 P63096 4/20 0.31
FAAH O00519 1/20 0.31
NAAA Q02083 1/20 0.31
F2 P00734 1/20 0.30
F9 P00740 1/20 0.30
F10 P00742 1/20 0.30
F12 P00748 1/20 0.30
PRSS1 P07477 1/20 0.30
PRSS2 P07478 1/20 0.30
F7 P08709 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18637142 0.84 SMN1; SMN2 (0.44) DPP4DPP7F2F9F10
SCHEMBL23658148 0.83 CHRNB2 (0.37) DPP4CHRNB2CHRNA3CHRNA4CHRNB3
Hydrochloric Acid SCHEMBL17560462 0.75 DPP4 (0.43) DPP4CHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL8118934 0.75 GNAI3 (0.40) GNAI3GNAO1GNAI1FAAHNAAA
SCHEMBL6423254 0.74 PARP1 (0.35) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL6285457 0.73 GNAI3 (0.45) GNAI3GNAO1GNAI1FAAHNAAA
SCHEMBL17789313 0.73 CHRM5 (0.32)
SCHEMBL20179729 0.72 GNAI3 (0.47) GNAI3GNAO1GNAI1FAAHNAAA
SCHEMBL2850134 0.72 GNAI3 (0.47) GNAI3GNAO1GNAI1FAAHNAAA
SCHEMBL14574265 0.71 CHRM5 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210221848-A1 POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS SPERO THERAPEUTICS, INC. 2021-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210221848-A1 POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS PNISR, MRPS18A, MRPS35 DPP4 930/4885DPP7 1002/4885CHRNB2 4882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.